Molecular diagnosis is an important indicator for response to growth hormone therapy in children with short stature
Clinica Chimica Acta · 2024
DOI: 10.1016/j.cca.2024.117779 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinica Chimica Acta, 2024. Verfasst von Qianqian Zhao und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Genetics and Metabolism, Affiliated Hospital of Jining Medical University, Jining Medical University, 89 Guhuai Road, Ji…. Hauptthemen laut MEDLINE: Human Growth Hormone, Dwarfism. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Natural Science Foundation of Shandong Province.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
BACKGROUND: Significant differences have been observed in the efficacy of recombinant human growth hormone (rhGH) treatment for short children. The present study aimed to identify the genetic etiology of short stature and to assess the role of molecular diagnosis in predicting responses to rhGH treatment. METHODS: A total of 407 short children were included in the present study, 226 of whom received rhGH treatment. Whole-exome sequencing (WES) was conducted on short children to identify the underlying genetic etiology. Correlations between molecular diagnosis and the efficacy of rhGH treatment were examined. RESULTS: Pathogenic or likely pathogenic mutations were identified in 86 of the 407 patients (21.1%), including 36 (41.9%) novel variants. Among the multiple pathways affecting short stature, genes involved in fundamental cellular processes (38.7%) play a larger role, especially the RAS-MAPK pathway. In general, patients without pathogenic mutations responded better to rhGH than those with mutations. Furthermore, patients with hormone signaling pathway mutations had a better response to rhGH, while those with paracrine factor mutations had a worse response to rhGH. CONCLUSIONS: This study highlights the utility of WES in identifying genetic etiology in children with short stature. Identifying likely causal mutations is an important factor in predicting rhGH response.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology, Genetics and Metabolism, Affiliated Hospital of Jining Medical University, Jining Medical University, 89 Guhuai Road, Jining, Shandong 272029, PR China; Chinese Research Center for Behavior…
- Medical Research Center, Affiliated Hospital of Jining Medical University, 89 Guhuai Road, Jining, Shandong 272029, PR China.
- Department of Pediatrics and Adolescent Medicine, The University of Hong Kong, 21 Sassoon Road, Pokfulam 999077 Hong Kong, China. Electronic address: yangwl@hku.hk.
Förderung
- Natural Science Foundation of Shandong Province
Zitieren
APA
Zhao, Q., Zhang, M., Li, Y., Zhang, C., Zhang, Y., Shao, Q., Wei, W., Yang, W., & Ban, B. (2024). Molecular diagnosis is an important indicator for response to growth hormone therapy in children with short stature. Clinica Chimica Acta. https://doi.org/10.1016/j.cca.2024.117779
Vancouver
Zhao Q, Zhang M, Li Y, Zhang C, Zhang Y, Shao Q, et al. Molecular diagnosis is an important indicator for response to growth hormone therapy in children with short stature. Clinica Chimica Acta. 2024. doi:10.1016/j.cca.2024.117779
BibTeX
@article{Zhao2024,
author = {Zhao, Qianqian and Zhang, Mei and Li, Yanying and Zhang, Chuanpeng and Zhang, Yanhong and Shao, Qian and Wei, Wei and Yang, Wanling and Ban, Bo},
title = {Molecular diagnosis is an important indicator for response to growth hormone therapy in children with short stature},
journal = {Clinica Chimica Acta},
year = {2024},
doi = {10.1016/j.cca.2024.117779}
}
EUVIMED